TY - JOUR
T1 - Haematological cancers in pregnancy
AU - Brenner, Benjamin
AU - Avivi, Irit
AU - Lishner, Michael
N1 - Funding Information:
The research described in this article was carried out by the Jet Propulsion Laboratory, California Institute of Tech-nology and by Wright Laboratory, Wright Patterson Air Force Base. It was sponsored by the U.S. Air Force and the National Aeronautics and Space Administration.
PY - 2012
Y1 - 2012
N2 - Haematological cancer in pregnancy, although rare, poses a substantial risk to both mother and fetus. Hodgkin's lymphoma is the most common, followed by non-Hodgkin lymphoma and acute leukaemia. Diagnosis of haematological cancers is challenged by an overlap of the disease and gestation-related symptoms and limitations of imaging studies in pregnancy. Data for safety and effectiveness of therapy are scarce and mostly retrospective. This report provides updated guidance for management, focusing on chemotherapy and biological agents. The primary goal of treatment is to preserve the mother's health; hence, pregnancy termination is often advisable at early stages, allowing delivery of adequate therapy. However, at later gestational stages treatment is often feasible. Pregnancy-related hypercoagulability, augmented by cancer, often necessitates thromboprophylaxis. The consequences and complex management of haematological cancer during pregnancy emphasise the need for collaborative research, focusing on basic mechanisms of disease and prospective epidemiological studies.
AB - Haematological cancer in pregnancy, although rare, poses a substantial risk to both mother and fetus. Hodgkin's lymphoma is the most common, followed by non-Hodgkin lymphoma and acute leukaemia. Diagnosis of haematological cancers is challenged by an overlap of the disease and gestation-related symptoms and limitations of imaging studies in pregnancy. Data for safety and effectiveness of therapy are scarce and mostly retrospective. This report provides updated guidance for management, focusing on chemotherapy and biological agents. The primary goal of treatment is to preserve the mother's health; hence, pregnancy termination is often advisable at early stages, allowing delivery of adequate therapy. However, at later gestational stages treatment is often feasible. Pregnancy-related hypercoagulability, augmented by cancer, often necessitates thromboprophylaxis. The consequences and complex management of haematological cancer during pregnancy emphasise the need for collaborative research, focusing on basic mechanisms of disease and prospective epidemiological studies.
UR - http://www.scopus.com/inward/record.url?scp=84856914452&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(11)61348-2
DO - 10.1016/S0140-6736(11)61348-2
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 22325663
AN - SCOPUS:84856914452
SN - 0140-6736
VL - 379
SP - 580
EP - 587
JO - The Lancet
JF - The Lancet
IS - 9815
ER -